美國居民不適用 XM 服務。
T
T

ThermoFisher


財經新聞

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation

BRIEF-Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation May 31 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC UPDATES CHROMOSOMAL MICROARRAY ANALYSIS SOLUTIONS TO COMPLY WITH IVDR REGULATION THERMO FISHER SCIENTIFIC INC: APPLIED BIOSYSTEMS™ CYTOSCAN™ DX AND CHROM
T

Bluebird bio appoints new CFO to oversee financial restatements

UPDATE 2-Bluebird bio appoints new CFO to oversee financial restatements Adds background throughout May 29 (Reuters) - Gene therapy maker bluebird bio BLUE.O on Wednesday named former Renalytix RENX.L finance chief James Sterling as its CFO to oversee the revision of the company's financial statements. Sterling will take over on June 10 from incumbent Chris Krawtschuk, who was in the role from November 2022. The company announced its plans to revise its financial statements in March, citing "mat
G
T

Ultragenyx must face Henrietta Lacks family lawsuit over HeLa cell profits

CORRECTED-Ultragenyx must face Henrietta Lacks family lawsuit over HeLa cell profits Corrects Ultragenyx attorneys' law firm information By Blake Brittain May 20 (Reuters) - The estate of Henrietta Lacks can move forward with a lawsuit against biopharmaceutical company Ultragenyx RARE.O over the use of cells taken from Lacks' body in the 1950s, a Maryland federal court said on Monday.
T

UK's CMA kicks off probe into Thermo Fisher-Olink deal

UK's CMA kicks off probe into Thermo Fisher-Olink deal May 10 (Reuters) - Britain's competition regulator said on Friday it has initiated a probe into U.S. medical equipment maker Thermo Fisher Scientific's TMO.N $3.1 billion deal to buy Swedish biotech firm Olink Holding AB OLK.O . The Competition and Markets Authority (CMA) has set a deadline of July 8 for its phase 1 decision.
T

UK's CMA Starts Merger Investigation Into Thermo Fisher/Olink Deal

BRIEF-UK's CMA Starts Merger Investigation Into Thermo Fisher/Olink Deal May 10 (Reuters) - Competition and Markets Authority (CMA): START OF CMA MERGER INVESTIGATION: THERMO FISHER SCIENTIFIC / OLINK DEADLINE OF 08 JULY 2024 FOR ITS PHASE 1 DECISION. FOR THERMO FISHER/OLINK DEAL Source text for Eikon: ID:nRSJ8561Na Further company coverage: TMO.N
T

Waters Corp beats quarterly estimates on strong demand for drug development services

Waters Corp beats quarterly estimates on strong demand for drug development services May 7 (Reuters) - Waters Corp WAT.N beat Wall Street estimates for first-quarter results on Tuesday, helped by strong demand for its services used in drug development and research. Drug contract manufacturers such as Waters saw reduced spending from their biotech clients last year due to higher interest rates.
T
W

Becton Dickinson lifts profit view on strong surgical equipment demand

Becton Dickinson lifts profit view on strong surgical equipment demand May 2 (Reuters) - Becton Dickinson BDX.N raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes. Medical technology firms like Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, undergo surgeries that were put on hold during the
A
B
T

Anti-obesity drugmakers savor pandemic leftovers

BREAKINGVIEWS-Anti-obesity drugmakers savor pandemic leftovers The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, May 1 (Reuters Breakingviews) - Eli Lilly LLY.N and Novo Nordisk NOVOb.CO have a luxury problem, one they’re solving quickly. The two drugmakers worth a combined $1.2 trillion cannot produce enough of their injectable anti-obesity treatments to meet extraordinary demand.
B
T

Thermo Fisher Scientific Extends Expiration Of Tender Offer

BRIEF-Thermo Fisher Scientific Extends Expiration Of Tender Offer May 1 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXTENDS THE EXPIRATION OF TENDER OFFER FOR ALL OUTSTANDING COMMON SHARES AND ADSS OF OLINK THERMO FISHER SCIENTIFIC INC - OFFER NOW SCHEDULED TO EXPIRE AT 5:00 P.M., NEW YORK TIME, ON JUNE 18, 2024 Source
T

Bio-Techne beats third-quarter estimates on improving demand for biotech products

Bio-Techne beats third-quarter estimates on improving demand for biotech products May 1(Reuters) - Bio-Techne TECH.O on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices. On an adjusted basis, the company posted a profit of 48 cents per share, beating analysts' estimates of 45 cents per share, according to LSEG data.
T

Street View: Thermo Fisher's 2024 'setup looks good'

BUZZ-Street View: Thermo Fisher's 2024 'setup looks good' ** Thermo Fisher TMO.N on Wednesday beat Wall Street estimates for quarterly profit and raised its annual profit forecast, betting on improved demand for its products and services used in drug development ** TMO now expects annual adj. profit of $21.14 to $22.02 per share, compared with previous forecast of $20.95 to $22 per share ** Median PT of 28 brokerages covering stock is $615 - LSEG data CHINA STIMULUS COULD BE 'CHERRY ON TOP' ** M
T

Thermo Fisher Scientific Inc reports results for the quarter ended in March - Earnings Summary

Thermo Fisher Scientific Inc reports results for the quarter ended in March - Earnings Summary Thermo Fisher Scientific Inc TMO.N reported quarterly adjusted earnings of $5.11​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $5.03. The mean expectation of twenty one analysts for the quarter was for earnings of $4.71 per share.
T

Thermo Fisher rises on Q1 profit beat, raises annual profit forecast

BUZZ-Thermo Fisher rises on Q1 profit beat, raises annual profit forecast ** Shares of medical equipment maker Thermo Fisher Scientific's TMO.N rise 1.5% to $583 premarket ** Co raises annual adj. EPS forecast to $21.14-$22.02 vs. previous forecast of $20.95-$22 ** Co posted Q1 adj. EPS of $5.11, beating est. of $4.71, as per LSEG data, helped by n
T

Thermo Fisher lifts profit forecast as medical equipment demand improves

Thermo Fisher lifts profit forecast as medical equipment demand improves April 24 (Reuters) - Thermo Fisher TMO.N on Wednesday beat Wall Street estimates for quarterly profit and raised its annual profit forecast, betting on improved demand for its products and services used in drug development and sending shares up about 4% premarket. The medical equipment maker in January signaled that muted demand for its services used in the making of therapies and vaccines will extend at least into the firs
T

Thermo Fisher Q1 Adjusted EPS USD 5.11 Vs. IBES Estimate USD 4.71

BRIEF-Thermo Fisher Q1 Adjusted EPS USD 5.11 Vs. IBES Estimate USD 4.71 Apr 24 (Reuters) - Thermo Fisher Q1 adjusted EBIT USD 2,278 million vs. IBES estimate USD 2,127 million. Q1 revenue USD 10,345 million vs. IBES estimate USD 10,170 million Q1 EPS USD 3.46 Q1 adjusted net income USD 1,959 million vs. IBES estimate USD 1,825 million outlook FY ad
T

What to Watch in the Day Ahead - Wednesday, April 24

What to Watch in the Day Ahead - Wednesday, April 24 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Meta Platforms' revenue is expected to grow 26% as AI investments drive higher engagement at Instagram and gains through its advertising platform.
A
A
B
B
C
G
H
T
A
U

Danaher beats quarterly estimates on strength in diagnostics business

Danaher beats quarterly estimates on strength in diagnostics business April 23 (Reuters) - Danaher DHR.N beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the bell. However, the company forecast a low single-digit percentage decline in its 2024 adjusted core revenue, as it expects the impact of reduced demand to continue into the second quarter of 2024. Danah
T

Thermo Fisher Scientific Inc <TMO.N> expected to post earnings of $4.71 a share - Earnings Preview

Thermo Fisher Scientific Inc expected to post earnings of $4.71 a share - Earnings Preview Thermo Fisher Scientific Inc TMO.N , TMO is expected to show a fall in quarterly revenue when it reports results on April 24 for the period ending March 31 2024 The Waltham Massachusetts-based company is expected to report a 5.0% decrease in revenue to $10.17 billion from $10.71 billion a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
T

What to Watch in the Week Ahead and on Monday, April 22

What to Watch in the Week Ahead and on Monday, April 22 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Tesla chief Elon Musk is expected to meet with India's Prime Minister Narendra Modi and announce plans to invest in and build a factory in the country.
A
B
B
C
G
G
G
H
I
P
S
K
H
T
A
A
U

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling Of Cell Therapy Manufacturing

BRIEF-Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling Of Cell Therapy Manufacturing April 11 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC INTRODUCES ANIMAL ORIGIN-FREE FORMULATION TO SUPPORT SCALING OF CELL THERAPY MANUFACTURING THERMO FISHER SCIENTIFIC INC - INTRODUCED GIBCO™ CTS
T



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明